GSK (GSK) announced an agreement granting GSK exclusive worldwide rights to develop and commercialise a preclinical ADC for mCRPC. The novel ADC, which utilises Syndivia’s next-generation GeminiMab conjugation technology, has shown enhanced anti-tumour activity and an encouraging safety profile, demonstrating best-in-class potential. In preclinical studies, the ADC was effective at shrinking tumours without causing a proportional increase in significant side effects, even at higher doses. This ADC could provide a targeted treatment directly to the tumour, currently a gap in available therapies, along with a more easily accessible treatment in the community practice setting for mCRPC. Under the terms of the agreement, Syndivia will receive an upfront payment as well as success-based development and commercial milestone payments up to a total of GBP 268 million. They will also receive tiered royalties on future product sales worldwide. GSK will assume full responsibility for the development, manufacturing, and worldwide commercialisation of the ADC program.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK Earnings this Week: How Will it Perform?
- Sell Rating for GlaxoSmithKline Due to Limited Growth Prospects for Blenrep Amid Competitive Challenges and Regulatory Hurdles
- Sell Rating Issued for GlaxoSmithKline’s Blenrep Due to Restrictive Approval and Market Limitations
- GSK’s Blenrep approved by FDA for treatment of relapsed multiple myeloma
- GSK’s New RSV Vaccine Study: A Potential Game-Changer for Investors